Education
About Us
Working with TipRanks
Follow Us
Armata Pharmaceuticals Inc (ARMP)
XASE:ARMP
ARMP Stock Chart & Stats
$3.48
$0.11(5.39%)
At close: 4:00 PM EST
$3.48
$0.11(5.39%)
Day’s Range― - ―
52-Week Range$0.90 - $16.34
Previous CloseN/A
Volume48.90K
Average Volume (3M)536.86K
Market Cap
$228.64M
Enterprise Value$270.88M
Total Cash (Recent Filing)$14.76M
Total Debt (Recent Filing)$177.68M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Mar 19, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding36,406,906
10 Day Avg. Volume121,090
30 Day Avg. Volume536,864
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-1.39
Price to Sales (P/S)12.93
P/FCF Ratio-1.70
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue53.60
Enterprise Value/Gross Profit76.07
Enterprise Value/Ebitda-8.92
Forecast
1Y Price Target
$9.00Price Target Upside158.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsNew data strongly support advancement of AP-SA02 into a pivotal Phase 3 trial, which the company plans to initiate pending FDA review and feedback.
Operational MilestoneThe formal commission of its state-of-the-art cGMP phage manufacturing facility is viewed as a positive operational milestone.
Therapeutic PotentialIDWeek 2025 data from the diSArm study further reinforced AP-SA02's therapeutic potential.
Bears Say
Earnings MissArmata announced 3Q25 financial results, posting EPS of ($0.74) compared to an estimate of ($0.42), due to a non-cash charge related to its convertible loan.
Financial PerformanceArmata announced 3Q25 financial results, posting EPS of ($0.74) compared to analyst estimate of ($0.42).
Armata Pharmaceuticals News
ARMP FAQ
What was Armata Pharmaceuticals Inc’s price range in the past 12 months?
Armata Pharmaceuticals Inc lowest stock price was $0.90 and its highest was $16.34 in the past 12 months.
What is Armata Pharmaceuticals Inc’s market cap?
Armata Pharmaceuticals Inc’s market cap is $228.64M.
When is Armata Pharmaceuticals Inc’s upcoming earnings report date?
Armata Pharmaceuticals Inc’s upcoming earnings report date is Mar 19, 2026 which is in 83 days.
How were Armata Pharmaceuticals Inc’s earnings last quarter?
Armata Pharmaceuticals Inc released its earnings results on Nov 12, 2025. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.42 by -$0.32.
Is Armata Pharmaceuticals Inc overvalued?
According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued.
Does Armata Pharmaceuticals Inc pay dividends?
Armata Pharmaceuticals Inc does not currently pay dividends.
What is Armata Pharmaceuticals Inc’s EPS estimate?
Armata Pharmaceuticals Inc’s EPS estimate is -0.19.
How many shares outstanding does Armata Pharmaceuticals Inc have?
Armata Pharmaceuticals Inc has 36,406,906 shares outstanding.
What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?
Armata Pharmaceuticals Inc reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.42. Following the earnings report the stock price went down -4.634%.
Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ARMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Armata Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (158.62% Upside)
$9.00 (158.62% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.88%
Trailing 12-Months
Company Description
Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for the treatment of bacterial infections. The company specializes in harnessing the power of bacteriophage technology, which utilizes viruses that specifically target and kill bacteria. Armata's core product offerings include its proprietary phage therapies designed to address antibiotic-resistant infections, with an emphasis on personalized medicine approaches to combat specific pathogens.
ARMP Stock 12 Month Forecast
Average Price Target
$9.00
▲(158.62% Upside)
Technical Analysis
Ownership Overview
0.63% Insiders
1.06% Mutual Funds
0.58% Other Institutional Investors
96.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---